Phase 3 Cardiovascular Risk Clinical Trials
6 recruitingPhase 3
What is a Phase 3 trial?
Phase 3 trials compare the new treatment against the current standard of care in large groups, often hundreds to thousands of participants. Successful Phase 3 results are typically required for regulatory approval.
Showing 1–6 of 6 trials
Recruiting
Phase 3
Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease
HypertensionHigh Risk Cardiovascular DiseaseHigh Cardiovascular Risk
Alnylam Pharmaceuticals11,000 enrolled597 locationsNCT07181109
Recruiting
Phase 3
ARTEMIS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With a Heart Attack
Cardiovascular RiskAcute Myocardial Infarction (AMI)
Novo Nordisk A/S10,000 enrolled970 locationsNCT06118281
Recruiting
Phase 3
Effect of Metformin Use on Weight Loss in Obese, Non-diabetic People (MOWRI)
Insulin ResistanceObesity and Cardiovascular RiskObesity (Body Mass Index >30 kg/m2)
University Of Nigeria Teaching Hospital220 enrolled2 locationsNCT07297290
Completed
Phase 3
The effect of 30 day krill oil supplementation on cardiovascular risk factors
Metabolic and EndocrineCardiovascular risks
Victoria University30 enrolled1 locationACTRN12615000472572
Recruiting
Phase 3
A large-scale trial testing the intensity of CYTOreductive therapy to prevent cardiovascular events In patients with Polycythemia Vera (PV)
To assess the benefit/risk profile of cytoreductive therapy with phlebotomy and/or hydroxyurea (HU) aimed at maintaining hematocrit (HCT) < 45% Vs. maintaining HCT in the range of 45-50% in patients with PV treated at the best of recommended therapies (e.g., low dose of aspirin when indicated and adequated control of standard cardiovascular risk factors)
Consorzio Mario Negri Sud1,000 enrolled1 locationACTRN12609000046202
Recruiting
Phase 3
Long term impact of RAS inhibition on cardio-renal outcomes: a comparative trial of angiotensin converting enzyme inhibitors, angiotensin receptor blockers or combined therapy with both agents in patients with one or more cardiovascular risk factors and microalbuminuria, diabetic or not diabetic.
Patients with one or more cardiovascular risk factors and microalbuminuria, diabetic or not diabetic.
Consorzio Mario Negri Sud2,100 enrolled1 locationACTRN12607000333415